Jeong, M.-S., Baek, S.-W., Yang, G.-E., Mun, J.-Y., Kim, J. A., Kim, T.-N., Nam, J.-K., Choi, Y.-H., Lee, J.-S., Chu, I.-S., & Leem, S.-H. (2025). Chemoresistance-motility signature of molecular evolution to chemotherapy in non-muscle-invasive bladder cancer and its clinical implications. Cancer Letters, 610, 217339. https://doi.org/10.1016/j.canlet.2024.217339

Panebianco, V., Briganti, A., Efstathiou, J., Galgano, S., Luk, L., Muglia, V. F., Redd, B., de Rooij, M., Takeuchi, M., Woo, S., Witjes, J. A., & Vargas, H. A. (2024). The Role of Multiparametric Magnetic Resonance Imaging and the Vesical Imaging-Reporting and Data System (VI-RADS) in the Management of Patients with Bladder Cancer: Vision of the American College of Radiology VI-RADS Steering Committee. European Urology, 86(6), 485–487. https://doi.org/10.1016/j.eururo.2024.09.013

Anderson, C. B. (2024). What Is the Future of Cystoscopy for Detecting Urothelial Carcinoma? Journal of Urology, 212(3), 399–400. https://doi.org/10.1097/ju.0000000000004071

Plumber, S. A., Tate, T., Al-Ahmadie, H., Chen, X., Choi, W., Basar, M., Lu, C., Viny, A., Batourina, E., Li, J., Gretarsson, K., Alija, B., Molotkov, A., Wiessner, G., Lee, B. H. L., McKiernan, J., McConkey, D. J., Dinney, C., Czerniak, B., & Mendelsohn, C. L. (2024). Rosiglitazone and trametinib exhibit potent anti-tumor activity in a mouse model of muscle invasive bladder cancer. Nature Communications, 15(1). https://doi.org/10.1038/s41467-024-50678-2

Ingram, J. W., Chung, R., Laplaca, C., McKiernan, J. M., Lenis, A. T., & Anderson, C. B. (2024). Incidence and management of prostatic urethra recurrence in a cohort of 21 patients who received BCG induction for non-muscle invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 42(9), 290.e11-290.e16. https://doi.org/10.1016/j.urolonc.2024.04.017

Liu, M. A., Li, J. W., & Runcie, K. (2024). Management of Oligometastatic and Locally Recurrent Urothelial Carcinoma. Current Oncology Reports, 26(5), 496–503. https://doi.org/10.1007/s11912-024-01523-8

Lenis, A. T., Whiting, K., Ravichandran, V., Tallman, J. E., Alam, S. M., Chu, C. E., Jesus Escano, M. D., Bochner, E., Katims, A., Reisz, P. A., Truong, H., Clinton, T. N., Telis, L., Dason, S., McPherson, V., Teo, M. Y., Funt, S., Aggen, D., Goh, A. C., … Pietzak, E. J. (2024). Natural History and Genomic Landscape of Chemotherapy-Resistant Muscle-Invasive Bladder Cancer. JCO Precision Oncology, 8. https://doi.org/10.1200/po.23.00274

Oliver-Krasinski, J. M., Bidot, S., Ingram, J. W., O’Toole, K. M., McKiernan, J. M., Tinsley, M., & Harik, L. R. (2023). Noninvasive Papillary Urothelial Carcinoma of the Bladder: An Institutional Experience Focusing on Tumors With Borderline Features. Archives of Pathology & Laboratory Medicine, 148(2), 223–229. https://doi.org/10.5858/arpa.2022-0268-oa

Gore, J. L., Follmer, K., Reynolds, J., Nash, M., Anderson, C. B., Catto, J. W. F., Chamie, K., Daneshmand, S., Dickstein, R., Garg, T., Gilbert, S. M., Guzzo, T. J., Kamat, A. M., Kates, M. R., Lane, B. R., Lotan, Y., Mansour, A. M., Master, V. A., Montgomery, J. S., … Smith, A. B. (2024). Interruptions in bladder cancer care during the COVID-19 public health emergency. Urologic Oncology: Seminars and Original Investigations, 42(4), 116.e17-116.e21. https://doi.org/10.1016/j.urolonc.2023.11.010

Guercio, B. J., Sarfaty, M., Teo, M. Y., Ratna, N., Duzgol, C., Funt, S. A., Lee, C.-H., Aggen, D. H., Regazzi, A. M., Chen, Z., Lattanzi, M., Al-Ahmadie, H. A., Brannon, A. R., Shah, R., Chu, C., Lenis, A. T., Pietzak, E., Bochner, B. H., Berger, M. F., … Iyer, G. (2023). Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience. Clinical Cancer Research, 29(22), 4586–4595. https://doi.org/10.1158/1078-0432.ccr-23-1283

Goubet, A.-G., Rouanne, M., Derosa, L., Kroemer, G., & Zitvogel, L. (2023). From mucosal infection to successful cancer immunotherapy. Nature Reviews Urology, 20(11), 682–700. https://doi.org/10.1038/s41585-023-00784-5

Bandara, N. A., Zhou, X. R., Alhamam, A., Black, P. C., & St-Laurent, M.-P. (2023). The genitourinary impacts of electronic cigarette use: a systematic review of the literature. World Journal of Urology, 41(10), 2637–2646. https://doi.org/10.1007/s00345-023-04546-1

Necchi, A., Faltas, B. M., Slovin, S. F., Meeks, J. J., Pal, S. K., Schwartz, L. H., Huang, R. S. P., Li, R., Manley, B., Chahoud, J., Ross, J. S., & Spiess, P. E. (2023). Immunotherapy in the Treatment of Localized Genitourinary Cancers. JAMA Oncology, 9(10), 1447. https://doi.org/10.1001/jamaoncol.2023.2174

Chung, R., Moran, G. W., Movassaghi, M., Pohl, D., Ingram, J., Lenis, A. T., McKiernan, J. M., Anderson, C. B., & Faiena, I. (2023). Survival outcomes in patients with muscle invasive bladder cancer undergoing radical vs. partial cystectomy. Urologic Oncology: Seminars and Original Investigations, 41(8), 356.e11-356.e18. https://doi.org/10.1016/j.urolonc.2023.04.017

Chung, R., McKiernan, J., Arpaia, N., Marabelle, A., & Rouanne, M. (2023). Neo-Adjuvant immunotherapies: Bladder cancer as a platform for drug development targeting mucosal immunity. European Journal of Cancer, 187, 58–64. https://doi.org/10.1016/j.ejca.2023.03.037

Pérez-Montiel, D., Olivares-Mundo, A., Jiménez-Ríos, M. A., Morera, C. S., Scavuzzo, A., Orozco-Mora, A., Prada, D., & Cantú-de León, D. (2023). Influence of luminal and basal subtype in prognosis of high-grade non muscle invasive urothelial carcinoma. Annals of Diagnostic Pathology, 63, 152081. https://doi.org/10.1016/j.anndiagpath.2022.152081

Girard, A., Dercle, L., Vila-Reyes, H., Schwartz, L. H., Girma, A., Bertaux, M., Radulescu, C., Lebret, T., Delcroix, O., & Rouanne, M. (2022). A machine-learning-based combination of criteria to detect bladder cancer lymph node metastasis on [18F]FDG PET/CT: a pathology-controlled study. European Radiology, 33(4), 2821–2829. https://doi.org/10.1007/s00330-022-09270-9

Han, D. S., Johnson, J. P., Schulster, M. L., & Shah, O. (2022). Indications for and results of renal autotransplantation. Current Opinion in Nephrology & Hypertension, 32(2), 183–192. https://doi.org/10.1097/mnh.0000000000000860

Joshi, M., Tuanquin, L., Zhu, J., Walter, V., Schell, T., Kaag, M., Kilari, D., Liao, J., Holder, S. L., Emamekhoo, H., Sankin, A., Merrill, S., Zheng, H., Warrick, J., Hauke, R., Gartrel, B., Stein, M., Drabick, J., Degraff, D. J., & Zakharia, Y. (2023). Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023. Journal for ImmunoTherapy of Cancer, 11(2), e006551. https://doi.org/10.1136/jitc-2022-006551

Alì, A., Leibowitz, D., Bhatt, N., Doubrovin, M., Spina, C. S., Bates-Pappas, G. E., Taub, R. N., McKiernan, J. M., Mintz, A., & Molotkov, A. (2022). Preliminary efficacy of [90Y]DOTA-biotin-avidin radiotherapy against non-muscle invasive bladder cancer. European Journal of Nuclear Medicine and Molecular Imaging, 50(3), 692–700. https://doi.org/10.1007/s00259-022-06027-w

Chung, R., Moran, G. W., Wang, C., McKiernan, J. M., & Anderson, C. B. (2022). Partial cystectomy: Review of a single center experience from 2004 to 2019. Urologic Oncology: Seminars and Original Investigations, 40(12), 538.e1-538.e5. https://doi.org/10.1016/j.urolonc.2022.09.003

Bahmad, H. F., Lopez, O., Moreno, J. C. A., Lopez, K., Malik, F., Salami, A., Nieder, A. M., Omarzai, Y., & Poppiti, R. J. (2022). Clinicopathological analysis of recurrence and progression of low-grade papillary urothelial carcinoma of the urinary bladder: Predicting the outcome. Annals of Diagnostic Pathology, 61, 152030. https://doi.org/10.1016/j.anndiagpath.2022.152030

Anderson, C. B., Chen, L., Chang, S. S., McKiernan, J. M., & Wright, J. (2022). Intravesical Therapy Compared to Radical Cystectomy Among Patients With Non-Muscle Invasive Bladder Cancer Requiring Additional Treatment After Induction BCG. Clinical Genitourinary Cancer, 20(6), 595–603. https://doi.org/10.1016/j.clgc.2022.07.001

Salomé, B., Sfakianos, J. P., Ranti, D., Daza, J., Bieber, C., Charap, A., Hammer, C., Banchereau, R., Farkas, A. M., Ruan, D. F., Izadmehr, S., Geanon, D., Kelly, G., de Real, R. M., Lee, B., Beaumont, K. G., Shroff, S., Wang, Y. A., Wang, Y., … Horowitz, A. (2022). NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer. Cancer Cell, 40(9), 1027-1043.e9. https://doi.org/10.1016/j.ccell.2022.08.005

Pohar, K. S., Patel, S., Lotan, Y., Trabulsi, E., Woods, M., Downs, T., Huang, W. C., Jones, J., Taylor, J., O’Donnell, M., Bivalacqua, T. J., DeCastro, J., Steinberg, G., Kamat, A. M., Resnick, M. J., Konety, B., Schoenberg, M., Jones, J. S., & Daneshmand, S. (2022). Safety of repeat blue light cystoscopy with hexaminolevulinate (HAL) in the management of bladder cancer: Results from a phase III, comparative, multi-center study. Urologic Oncology: Seminars and Original Investigations, 40(8), 382.e1-382.e6. https://doi.org/10.1016/j.urolonc.2022.04.012

Rouanne, M., Adam, J., Radulescu, C., Letourneur, D., Bredel, D., Mouraud, S., Goubet, A.-G., Leduc, M., Chen, N., Tan, T. Z., Signolle, N., Bigorgne, A., Dussiot, M., Tselikas, L., Susini, S., Danlos, F.-X., Schneider, A. K., Chabanon, R., Vacher, S., … Marabelle, A. (2022). BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer. Journal of Clinical Investigation, 132(12). https://doi.org/10.1172/jci145666

Singhal, S., Ruprecht, N. A., Sens, D., Tavakolian, K., Gardner, K. L., & Singhal, S. K. (2022). Association between Arsenic Level, Gene Expression in Asian Population, and In Vitro Carcinogenic Bladder Tumor. Oxidative Medicine and Cellular Longevity, 2022, 1–26. https://doi.org/10.1155/2022/3459855